Overview

Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis.

Status:
Completed
Trial end date:
2020-03-19
Target enrollment:
Participant gender:
Summary
Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis
Phase:
Phase 2
Details
Lead Sponsor:
Novo Nordisk A/S